Lisocabtagene maraleucel: A cost-effective second-line treatment for relapsed/refractory DLBCL

Lisocabtagene maraleucel (liso-cel), a CAR T-cell therapy, is a cost effective second line treatment for relapsed and refractory (hard to treat) diffuse large B-cell lymphoma (r/r DLBCL), according to a study published today in Blood Advances.

Intuitive’s venture capital arm launches second investment fund

Listen to the article 2 min This audio is auto-generated. Please let us know if you have feedback. Dive Brief: Intuitive Surgical’s venture capital arm

December 5, 2023

Psyched Wellness Developing Amanita Muscaria Gummies for Sale in the USA | Psychedelic Invest

Toronto, Ontario–(Newsfile Corp. – June 13, 2024) – Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the “Company” or “Psyched“), a life sciences company

June 13, 2024

Lactate-producing intratumoral bacteria drive resistance to radiation therapy

Researchers at The University of Texas MD Anderson Cancer Center have discovered that lactate-producing intratumoral bacteria drives resistance to radiation therapy, suggesting that lactic acid-producing

October 19, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.